An activated partial thromboplastin clotting time (APTT) can be abnormal in a heterogeneous group of disorders. Risks associated with a prolonged APTT include hemorrhage or thrombosis, or the prolongation can have no hemostatic consequence. An abnormal APTT should always be evaluated within the context of the patient’s clinical history.
Mayo Clinic hematologists, hematopathologists, and a wide spectrum of allied health staff are in San Francisco for the 56th American Society of Hematology Annual Meeting & Exhibition. Follow this blog for live updates from #ASH14 as we attend the conference, mingle with colleagues at booth #2637, and have a little fun.
We will have representatives at booth #2637 in the exhibit hall to discuss the latest developments and test offerings for hematologic disorders. If you are unable to attend this year's meeting, our in-booth informational resources are linked in this post.
Mayo Clinic Symposium at ASH: Presentations Now Available
Precision and Reliability of Platelet Function Tests on Daily Antiplatelet Agent Therapy
International Research Group Publishes Updated Criteria for Diagnosing Multiple Myeloma
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines
Novel BCR-ABL1 Fusion Identified by Targeted Next-Generation Sequencing in a Patient with an atypical Myeloproliferative Neoplasm